Thermo Fisher Profit up as Life Tech awaits

Laboratory equipment maker Thermo Fisher Scientific, which this month agreed to acquire Life Technologies for more than $13 billion, on Wednesday reported a higher-than-expected first-quarter profit, helped by a 10% rise in specialty diagnostics sales.

Excluding one-time items, Thermo Fisher posted earnings of $1.37 per share, topping analysts average expectations by 8 cents, according to Thomson Reuters I/B/E/S.

The company raised the low end of its full-year revenue view and lowered its 2013 earnings-per-share forecast to reflect its decision to suspend share buybacks as it prepares to pay for Life Tech. The $13.6 billion Life Tech acquisition, which will give Thermo Fisher a major presence in advanced genetic testing, is expected to close in early 2014.

Thermo Fisher now expects adjusted earnings of $5.27 to $5.39 per share, down from its prior view of $5.32 to $5.46 per share. It expects 2013 revenue of $12.84 billion to $13 billion. The low end of the previously announced range was $12.80 billion. Analysts are looking for earnings of $5.40 per share and revenue of $12.96 billion.

"The business is holding up very well considering the pressure on the industrial and academic (markets)," said Mizuho Securities analyst Peter Lawson. "On the flip side, the pharma business is doing exceptionally well."

The automatic U.S. budget cuts known as sequestration is expected to hurt academic and government research customers.

Thermo, on a conference call with analysts, said sequestration was likely to have a bigger impact over the rest of the year than it did in the first quarter.

The world's largest maker of laboratory equipment and scientific instruments reported a net profit from continuing operations of $340.8 million, or 94 cents per share, compared with a profit of $280.8 million, or 76 cents per share, a year earlier.

Revenue for the quarter rose 4% to $3.19 billion, roughly in line with Wall Street estimates of $3.17 billion.

Specialty Diagnostics saw sales rise 10% to $806 million, while sales from the Laboratory Products and Services unit rose 5% to $1.54 billion.

Sales from the Analytical Technologies unit fell to $978 million from $980 million a year ago, possibly reflecting an impact of sequestration.

Thermo said it was having a bigger impact on capital spending than on consumables and reagents used in biotech and pharmaceutical development.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.